Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection
Status:
Withdrawn
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The main purpose of the study is to evaluate the safety of oral auranofin, a gold compound,
in patients with HIV infection whose viral load has been suppressed by antiretroviral therapy
for no less than 3 years and have a CD4+ cell count over 500 cells/uL